This led us to hypothesize that administration of ICI would enhance LNP-CTNNB1 response in advanced-stage disease through limiting T cell exhaustion via PD1/PD-L1 axis, thus promoting sustained anti-tumor immunity. The gene discussed is CTNNB1; the disease is neoplasm.